Could a One-Time cell infusion tame lupus and other autoimmune diseases?

NCT ID NCT06308978

Recruiting now Disease control Sponsor: Fate Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study is testing a new cell therapy called FT819 for people with severe autoimmune diseases like lupus, vasculitis, and scleroderma. The treatment involves giving specially engineered immune cells along with chemotherapy drugs. The main goal is to see if it's safe and to find the right dose, with a secondary look at whether it can control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FT819 (a type of immune cell therapy made from stem cells, given by IV)
What this could lead to: If it works, this could point toward a new treatment option for people with severe autoimmune diseases like lupus that haven't responded to other therapies.
What could go wrong: This is a very early (Phase 1) trial, so the main goal is safety, not effectiveness. It's small and may not lead to a proven treatment. There are also risks from the chemotherapy drugs given alongside FT819.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired idiopathic inflammatory myopathy anti-neutrophil cytoplasmic antibody-associated vasculitis autoimmune disease granulomatosis with polyangiitis lupus nephritis myositis disease systemic lupus erythematosus systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANTINEUTROPHILIC CYTOPLASMIC ANTIBODY (ANCA)- ASSOCIATED VASCULITIS (AAV) IDIOPATHIC INFLAMMATORY MYOSITIS (IIM) LUPUS NEPHRITIS SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) SYSTEMIC SCLEROSIS (SSC)

Contacts and locations

Locations

Cambridge University Hospitals NHS Foundation Trust
RECRUITING

Cambridge, CB2 0QQ, United Kingdom
Children's Hospital Los Angeles Division Of Rheumatology
RECRUITING

Los Angeles, California, 90027, United States
Duke University Health System
RECRUITING

Durham, North Carolina, 27705, United States
Hôpital La Pitié Salpêtrière
RECRUITING

Paris, 75013, France
Jefferson Einstein Hospital Philadelphia
RECRUITING

Philadelphia, Pennsylvania, 19141, United States
Manchester University NHS Foundation Trust
RECRUITING

Manchester, Greater Manchester, M139WL, United Kingdom
MetroHealth
RECRUITING

Cleveland, Ohio, 44109, United States
Montefiore Medical Center
RECRUITING

New York, New York, 10467, United States
Nicklaus Children's Hospital
RECRUITING

Miami, Florida, 33155, United States
Providence Medical Foundation
RECRUITING

Fullerton, California, 92835, United States
Regional One Health
RECRUITING

Memphis, Tennessee, 38103, United States
University College of London Hospitals NHS Trust (UCLH)
RECRUITING

London, NW1 2PQ, United Kingdom
University of California Irvine
RECRUITING

Irvine, California, 92868, United States
University of California San Francisco
RECRUITING

San Francisco, California, 94110, United States
University of Florida
RECRUITING

Gainesville, Florida, 32610, United States
University of Louisville
RECRUITING

Louisville, Kentucky, 40202, United States
University of Minnesota Medical School
RECRUITING

Minneapolis, Minnesota, 55455, United States
University of Nebraska Medical Center
RECRUITING

Omaha, Nebraska, 68198, United States
University of Oklahoma
RECRUITING

Oklahoma City, Oklahoma, 73019, United States
Uppsala University
RECRUITING

Uppsala, Uppland, 752 37, Sweden
Wallace Rheumatic Center
RECRUITING

Beverly Hills, California, 90210, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.